ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2088

COVID-19 Infection in Kidney Transplant Patients: An Italian One-Year Single-Center Experience

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Campise, Mariarosaria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Alfieri, Carlo, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Cresseri, Donata Carmela, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Gandolfo, Maria Teresa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Binda, Valentina, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Regalia, Anna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
  • Messa, Piergiorgio, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy
Background

COVID-19 is a life-threatening infection among elderly, comorbid patients, or transplanted patients. Lombardy (Region of Italy), accounts for 786.324 cases as of April 21st, 2021.

Methods

We retrospectively describe our single Centre experience in 82 adult kidney-transplant patients with COVID-19 infection during two pandemic outbreaks: 27 (first outbreak) and 65 (second).

Results

Thirty-seven patients were hospitalized (HP) and 65 were home managed (HM). Infection presented with fever (80 %), cough (51 %) and dyspnea (33 %). HP were older (60±11vs 50±14 years, p=0,001), had more severe respiratory symptoms (dyspnea 62.1%, p<0.0001 – cough 67% p=0.008), and a longer length of disease (30±28 vs 21±10, p=0.04). Incidence of acute kidney injury (AKI) was 29.7% (p<0.0001). Steroid dosage was increased in 66% of patients, p=0.0003 while Calcineurin Inhibitors were reduced up to one third in 45% of cases, p<0.0001. Eleven patients died (13%). HM patients recovered completely without sequelae. In the overall cohort, AKI development (p=0.006 OR 50.4 CI 95% 3.0-836) and age (p=0.04 OR 1.1 CI 95% 1.0-1.2) were the most important factors influencing the probability of death during the infection.

Conclusion

Although we report a relatively low incidence of infection (5.1 %) incidence of death is almost four times higher than in general population.

Table 1: patients characteristics before COVID-19 infection.